David A. Roth
Net Worth
Last updated:
What is David A. Roth net worth?
The estimated net worth of Dr. David A. Roth is at least $1,565,959 as of 18 Nov 2024. He owns shares worth $57 as insider, has earned $139,842 from insider trading and has received compensation worth at least $1,426,060 in Syros Pharmaceuticals, Inc..
What is the salary of David A. Roth?
Dr. David A. Roth salary is $713,030 per year as Chief Medical Officer in Syros Pharmaceuticals, Inc..
How old is David A. Roth?
Dr. David A. Roth is 62 years old, born in 1963.
What stocks does David A. Roth currently own?
As insider, Dr. David A. Roth owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. (SYRS) | Chief Medical Officer | 10,451 | $0.01 | $57 |
What does Syros Pharmaceuticals, Inc. do?
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
David A. Roth insider trading
Syros Pharmaceuticals, Inc.
Dr. David A. Roth has made 6 insider trades between 2023-2024, according to the Form 4 filled with the SEC. Most recently he sold 12,099 units of SYRS stock worth $2,384 on 18 Nov 2024.
The largest trade he's ever made was exercising 18,875 units of SYRS stock on 31 Oct 2023. As of 18 Nov 2024 he still owns at least 10,451 units of SYRS stock.
Syros Pharmaceuticals key executives
Syros Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. David A. Roth (62) Chief Medical Officer
- Dr. Eric R. Olson (67) Chief Scientific Officer
- Dr. Nancy A. Simonian M.D. (64) Pres, Chief Executive Officer & Director
- Dr. Richard A. Young Ph.D. (71) Scientific Founder, Member of Scientific Advisory Board & Director